Kymera Therapeutics (KYMR) Times Interest Earned (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Times Interest Earned of -$0.2 for Q1 2026, up 66.41% year-over-year from -$0.12 in Q1 2025, and up 44.61% quarter-over-quarter from -$0.37 in Q3 2025.
Kymera Therapeutics (KYMR) Times Interest Earned (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Times Interest Earned for 8 consecutive years, with -$0.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 66.41% year-over-year to -$0.2; the TTM figure through Mar 2026 stood at -$0.87 (up 61.65% YoY), while the FY2025 annual figure was -$0.87, up 21.24% from the prior year.
- Times Interest Earned improved to -$0.2 in Q1 2026 per KYMR's latest filing, from -$0.37 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.2 in Q1 2026 and bottomed at -$5047.2 in Q4 2024.
- Historically, Times Interest Earned has averaged -$354.87 across 5 years, with a median of -$0.55 in 2025.
- Annual changes were most pronounced in 2023 — Times Interest Earned jumped 99.94% — and 2024, when it plunged 1296770.02%.
- Kymera Therapeutics' Times Interest Earned stood at -$623.06 in 2022, then surged by 99.94% to -$0.39 in 2023, then slumped by 1296770.02% to -$5047.2 in 2024, then surged by 99.99% to -$0.37 in 2025, then surged by 44.61% to -$0.2 in 2026.
- Business Quant data shows KYMR's Times Interest Earned at -$0.2 in Q1 2026, -$0.37 in Q3 2025, and -$0.63 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.12 |
| Mar 31, 2026 | -0.20 |
| Sep 30, 2025 | -0.37 |
| Jun 30, 2025 | -0.63 |
| Mar 31, 2025 | -0.61 |
| Dec 31, 2024 | -5,047.19 |
| Sep 30, 2024 | -0.48 |
| Jun 30, 2024 | -0.89 |
| Mar 31, 2024 | -0.44 |
| Dec 31, 2023 | -0.39 |
| Sep 30, 2023 | -0.45 |
| Jun 30, 2023 | -0.35 |
| Mar 31, 2023 | -0.68 |
| Dec 31, 2022 | -623.06 |
| Sep 30, 2022 | -0.91 |
| Jun 30, 2022 | -0.92 |
| Mar 31, 2022 | -0.28 |
| Dec 31, 2021 | -999.82 |
| Sep 30, 2021 | -0.12 |
| Jun 30, 2021 | -0.13 |